Oruka Therapeutics (NASDAQ:ORKA) Shares Up 9% – Here’s Why

Oruka Therapeutics, Inc. (NASDAQ:ORKA) rose 9% during mid-day trading on Thursday . The company traded as high as $69.72 and last traded at $69.7890. 253,552 shares were traded during trading, a decline of 76% from the average daily volume of 1,066,309 shares. The stock had previously closed at $64.03.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the company a “buy” rating in a research note on Monday, April 27th. Wedbush set a $165.00 price target on Oruka Therapeutics in a research report on Monday, April 27th. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 16th. Barclays boosted their price target on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, April 27th. Finally, Stifel Nicolaus boosted their price target on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and an average price target of $131.30.

Oruka Therapeutics Stock Performance

The firm has a market cap of $4.17 billion, a price-to-earnings ratio of -35.49 and a beta of -0.26. The company’s fifty day moving average is $62.62 and its two-hundred day moving average is $43.49.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. As a group, analysts forecast that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In related news, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the transaction, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock in a transaction on Monday, May 18th. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30. Following the transaction, the senior vice president owned 16,406 shares in the company, valued at $969,102.42. The trade was a 38.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 139,055 shares of company stock worth $8,095,785. Insiders own 23.49% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ORKA. Goldman Sachs Group Inc. acquired a new position in Oruka Therapeutics in the 1st quarter worth $2,505,000. JPMorgan Chase & Co. lifted its holdings in Oruka Therapeutics by 567.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock worth $173,000 after buying an additional 13,115 shares in the last quarter. Legal & General Group Plc acquired a new position in Oruka Therapeutics in the 2nd quarter worth $28,000. Rhumbline Advisers acquired a new position in Oruka Therapeutics in the 2nd quarter worth $320,000. Finally, New York State Common Retirement Fund acquired a new position in Oruka Therapeutics in the 2nd quarter worth $96,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.